Novogen Limited (NASDAQ:KZIA) Short Interest Update

Novogen Limited (NASDAQ:KZIA – Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 408,115 shares, a growth of 119.5% from the April 15th total of 185,921 shares. Based on an average daily volume of 343,000 shares, the short-interest ratio is presently 1.2 days. Currently, 24.9% of the company’s stock are short sold.

Novogen Stock Performance

Shares of KZIA opened at $13.16 on Friday. Novogen has a 1-year low of $3.24 and a 1-year high of $17.40. The company’s fifty day simple moving average is $9.87 and its 200 day simple moving average is $8.60.

Get Novogen alerts:

Novogen (NASDAQ:KZIA – Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported ($1.34) earnings per share for the quarter. The company had revenue of $4.89 million for the quarter. Equities analysts forecast that Novogen will post -0.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on KZIA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Novogen in a report on Wednesday, January 28th. Laidlaw assumed coverage on shares of Novogen in a report on Wednesday, April 15th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Novogen from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.00.

Check Out Our Latest Stock Report on Novogen

About Novogen

(Get Free Report)

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.

See Also

• Five stocks we like better than Novogen
• Viking Sails to All-Time Highs—Fundamentals Signal More to Come
• Datavalut Gains Traction: 5 Reasons to Sell Now
• TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
• The Power Grid Is Dying—Is It Time to Buy Its Replacement?

Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.